About Cessation Therapeutics
Cessation Therapeutics is a Healthcare company based in San Jose (United States) founded in 2017. Developer of immunotherapy based vaccines to manage addictions. Cessation Therapeutics has raised $6.76 million across 4 funding rounds from investors including HHS and National Institute on Drug Abuse. Its chief executive, as recorded, is John D Harkey. Cessation Therapeutics offers products and services including Anti-fentanyl Monoclonal Antibody. Its focus areas include Life Sciences, Immunotherapy, Antibody and Immunomodulatory. Its legal entity is CESSATION THERAPEUTICS, INC. Its competitors include Indivior, Forty Seven and Compass Therapeutics; 2 of its 3 listed competitors have raised funding.
Company details
Cessation Therapeutics was founded in 2017 and is headquartered in San Jose, United States. Focus is placed on biotechnology for developing immunotherapy vaccines targeting addiction disorders, including those related to opioids, heroin, morphine, fentanyl, alcohol, and nicotine. Drug conjugate molecules are created by linking haptens to immunogenic proteins, which are then formulated with immune stimulants to generate antibodies against substances of abuse and support immunity induction.
- Headquarters San Jose, United States
- SectorsHealthcare
- Email••••••••
- Website cessationtherapeutics.com
- Social LinkedIn
- Legal Name Cessation Therapeutics, Inc.
- Total Equity Funding$6.76M (USD)
in 4 rounds
- Latest Funding Round$1M (USD), Series A
Mar 2024
- InvestorsHHS
& 1 more
Products & Services of Cessation Therapeutics
Cessation Therapeutics offers a comprehensive portfolio of products and services, including Anti-fentanyl Monoclonal Antibody.
Antibody that captures fentanyl to prevent brain entry and overdose effects.
Funding Insights of Cessation Therapeutics
Cessation Therapeutics has successfully raised a total of $6.76M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $1 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $6.76M
- Total Rounds 4
- Last Round Series A — $1M
- First Round $210,621
(Jun 2019)
- Investors Count 2
All 4 funding rounds of Cessation Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in Cessation Therapeutics
Cessation Therapeutics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and National Institute on Drug Abuse.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Scientific research on drug use and addiction is supported. | drugabuse.gov | United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Cessation Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cessation Therapeutics
4 people are tracked at Cessation Therapeutics (4 in leadership).
| Name | Role | Group |
|---|---|---|
John D Harkey | Co-CEO | Leadership |
Andy Barrett, PhD | President & Chief Scientific Officer | Leadership |
David Genecov | Chief Medical Officer, Co-Founder and Director | Leadership |
Paul Bremer | Vice President, R&d And CMC | Leadership |
Complete people profiles for Cessation Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Cessation Therapeutics
3 dated milestones of Cessation Therapeutics across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Cessation Therapeutics is founded.
- Funding First funding round of $211K.
- Funding Latest funding round, Series A, of $1.0M.
Competitors of Cessation Therapeutics
Cessation Therapeutics has 3 listed competitors in our database, 2 of them funded. They include Indivior, Forty Seven and Compass Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| indivior.com | 2014 | Richmond Hill, United States | 1,051 | Therapeutics for opioid addiction treatment are developed and commercialized. | ||
| fortyseveninc.com | 2015 | Palo Alto, United States | $150M | 7,128 | Therapies for diverse diseases including oncology are developed. | |
| compasstherapeutics.com | 2013 | Cambridge, United States | $238.46M | 32 | Therapeutic antibodies for cancer treatment are discovered and developed. |
Detailed competitors of Cessation Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Cessation Therapeutics
The website of Cessation Therapeutics (cessationtherapeutics.com) receives about 2.1K visits a month.
- Monthly visits2.1K
▲ 10.5% vs previous month
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Cessation Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cessation Therapeutics
Complete news archive for Cessation Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cessation Therapeutics
Cessation Therapeutics was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Cessation Therapeutics is headquartered in San Jose, United States. It is registered at San Jose, California, United States.
John D Harkey is the CEO of Cessation Therapeutics, as recorded in our data.
Cessation Therapeutics is a funded company, having raised a total of $6.76M across 4 funding rounds to date. The company's 1st funding round was a Grant of $210.62K, raised on Jun 2019.
Cessation Therapeutics was founded in 2017 and is headquartered in San Jose, United States. Focus is placed on biotechnology for developing immunotherapy vaccines targeting addiction disorders, including those related to opioids, heroin, morphine, fentanyl, alcohol, and nicotine. Drug conjugate molecules are created by linking haptens to immunogenic proteins, which are then formulated with immune stimulants to generate antibodies against substances of abuse and support immunity induction.
Cessation Therapeutics's top competitors include Forty Seven, Indivior and Compass Therapeutics.
Cessation Therapeutics offers Anti-fentanyl Monoclonal Antibody.
Cessation Therapeutics has 2 investors. Key investors include HHS, and National Institute on Drug Abuse.
Cessation Therapeutics operates through Cessation Therapeutics, Inc..